Genome-wide association study implicates CHRNA2 in cannabis use disorder

Area of Science:

• Genetics
• Neuroscience
• Psychiatry

Background:

• Cannabis is a widely used psychoactive substance with a significant risk of dependence.
• Cannabis Use Disorder (CUD) exhibits substantial heritability, estimated between 51% and 70% from twin studies.

Purpose of the Study:

• To conduct a genome-wide association study (GWAS) to identify genetic risk loci for Cannabis Use Disorder (CUD).
• To investigate the association between genetic variants, gene expression, and CUD risk.
• To explore the polygenic relationship between cognitive performance and CUD susceptibility.

Main Methods:

• Performed a large-scale GWAS including 2,387 CUD cases and 48,985 controls, with subsequent replication in 5,501 cases and 301,041 controls.
• Utilized expression quantitative trait locus (eQTL) analysis to link genetic variants to gene expression, specifically for the CHRNA2 gene.
• Analyzed genetically regulated gene expression in brain tissue and assessed polygenic scores for cognitive performance.

Main Results:

• Identified a genome-wide significant risk locus for CUD (P = 9.31 × 10⁻¹²), which replicated in an independent population.
• The index variant rs56372821 is a strong eQTL for CHRNA2, with CHRNA2 expression significantly associated with CUD in brain tissue.
• A higher load of variants associated with cognitive performance correlated with a decreased risk of CUD.

Conclusions:

• The study elucidates a novel genetic risk locus for CUD, implicating the CHRNA2 gene.
• Findings suggest a biological link between CHRNA2 gene expression, brain function, and CUD susceptibility.
• Genetic architecture of CUD is complex, influenced by specific loci and potentially modulated by cognitive performance-related genetic factors.